Protective effect of recombinant thrombomodulin on chemotherapy-induced intestinal mucosal injury in mice

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B197
Abstract ID: 4213

Presenting Author:
Arong Gaowa , Assistant Prof. at Mie Univ.

Abstract:

Intestinal mucositis is a common side effect of chemotherapy. Cisplatin is an effective chemotherapeutic agent for various types of cancers. However, cisplatin-induced intestinal mucositis limits the dose of cisplatin and reduces its therapeutic efficacy. In this study, we investigated the protective effects of recombinant thrombomodulin (rTM), which is a potent anti-inflammatory agent, against cisplatin-induced intestinal mucositis and its possible molecular mechanisms. We first evaluated the effects of rTM on intestinal mucositis caused by cisplatin in mice. Disease progression was monitored by analyzing loss of body weight and histological changes in intestinal tissue. We then investigated the effects of rTM on mouse intestinal organoid formation and growth. Gene expression levels were analyzed by quantitative real-time polymerase chain reaction, Western blotting, and flow cytometry analysis. We found that rTM treatment significantly attenuated the loss of body weight, histological damage, and gene expression levels of pro-inflammatory cytokines such as interleukin-6, tumor necrosis factor-a and high-mobility group box-1 in a cisplatin-treated mouse model in vivo. Furthermore, rTM alleviated the inflammatory cytokine production and apoptosis in a cisplatin-treated intestinal epithelial organoid model in vitro. Taken together, rTM suppresses cisplatin-induced intestinal epithelial cell-derived cytokine production and alleviates intestinal mucositis.